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Progressive limb spasticity and cerebellar ataxia are frequently found together in clinical practice and form a heterogeneous group of
degenerative disorders that are classified either as pure spastic ataxia or as complex spastic ataxia with additional neurological signs.
Inheritance is either autosomal dominant or autosomal recessive. Hypomyelinating features on MRI are sometimes seen with spastic
ataxia, but this is usually mild in adults and severe and life limiting in children. We report seven individuals with an early-onset
spastic-ataxia phenotype. The individuals come from three families of different ethnic backgrounds. Affected members of two families
had childhood onset disease with very slow progression. They are still alive in their 30s and 40s and show predominant ataxia and
cerebellar atrophy features on imaging. Affected members of the third family had a similar but earlier-onset presentation associated
with brain hypomyelination. Using a combination of homozygozity mapping and exome sequencing, we mapped this phenotype to
deleterious nonsense or homeobox domain missense mutations in NKX6-2. NKX6-2 encodes a transcriptional repressor with early
high general and late focused CNS expression. Deficiency of its mouse ortholog results in widespread hypomyelination in the brain
and optic nerve, as well as in poor motor coordination in a pattern consistent with the observed human phenotype. In-silico analysis
of human brain expression and network data provides evidence that NKX6-2 is involved in oligodendrocyte maturation and might act
within the same pathways of genes already associated with central hypomyelination. Our results support a non-redundant develop-
mental role of NKX6-2 in humans and imply that NKX6-2mutations should be considered in the differential diagnosis of spastic ataxia
and hypomyelination.The clinical combination of hereditary spastic paraplegia
and cerebellar ataxia forms a frequent and heterogeneous
group of neurological conditions. Progression varies and
is often slowwhen affected individuals present in the adult
neurology setting, whereas in children the condition is
usually rapid and associated with other clinical features,
such as epilepsy, cognitive decline, dystonia, and hypo-
myelination on MRI.
Early and widespread clinical signs reflect the pivotal
position of myelination in the nervous system and the
need for adequate and measured myelination for many
critical functions1 and preservation of brain plasticity.2,3
Defects in myelin underlie many neurological disorders,
some acquired (e.g., immune-mediated destruction of
myelin in multiple sclerosis) and some congenital (e.g.,
inborn errors of myelin metabolism). The latter group of
hypomyelinating diseases is highly heterogeneous; the
phenotype depends on the site of involvement (central
nervous system versus peripheral nerves), severity, and
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ciency of myelin in the brain, as evident on MRI. The
archetypical example is Pelizaeus-Merzbacher disease
(PMD) (MIM: 312080), an X-linked disease caused by mu-
tations in the PLP1 (MIM: 300401), which codes for pro-
teolipid protein-1, a major component of myelin. Affected
individuals can present as neonates with severe hypotonia
and nystagmus or later with progressive spasticity and
ataxia. Mutations in other genes, such as SPG11 (MIM:
610844) or FA2H (MIM: 611026), causing spastic para-
plegia, can lead to a similar phenotype, but the imaging
is characteristically associated with thinning of the corpus
callosum. In many inherited spastic ataxias where the
affected gene is primarily involved in developmental pro-
cesses, the symptoms are often most predominant and
severe in children. In adults, once the myelination process
has ended, the disease is less progressive and often static.
Although a multitude of other genetic forms of hypomye-
linating leukodystrophies have been identified in recent
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In this study, we report three families with individuals
affected by autosomal-recessive spastic ataxia and for
whom MRI showed brain hypomyelination. In the
families described here we used a combination of homo-
zygosity mapping and exome sequencing to identify
and characterize the causal variants in NKX6-2 (MIM:
605955).
Unrelated individuals from three families were included
in our study. An early-onset progressive disorder was pre-
sent in all seven affected individuals. Initial and predomi-
nant features have always beenmotor related with variable
sparing of cognitive function (Table 1). Family 1 is of North
Indian descent. The two affected siblings presented with
spasticity, nystagmus, and ataxia. The older sibling, indi-
vidual 1 (III-1), achieved only initial motor milestones.
She was able to sit up but was never able to walk or run,
and she developed a complex spastic-ataxia phenotype.
The initial investigations revealed cerebellar atrophy on
MRI at the age of two years. The disease progressed, and
at the age of 27 she is wheelchair bound and has a severe
pyramidal syndrome involving predominantly the lower
limbs; associated features include nystagmus, hypometric
saccades, reduced up-gaze, very limited voluntary eye
movements, cerebellar dysarthria, titubation, and truncal
and limb ataxia with dystonic posturing and torticollis
(Supplemental Movie S1). Sensory examination is normal.
Her brother, individual 2 (III-2), has a similar but milder
phenotype. He started walking at 12 months, but by the
age of five years old he noticed difficulties with running,
and at 8 years old he needed a walking frame. The disease
progressed in a similar way to his sister, and he developed
additional cerebellar dysarthria and ataxia while in high
school. His cognitive function was within normal range;
he achieved ten top GCSE school grades. He is currently
22 years old and able to walk only a few steps with
maximum assistance. He has square-wave jerks and
marked gaze evoked nystagmus but is able to initiate eye
movements in any direction. There is retrocollis with ster-
nocleidomastoidian muscle hypertrophy and upper-limb
dystonia. In the lower limbs there is a severe pyramidal
syndrome and weakness. He has significant ataxia in
both upper and lower limbs. Cognitive function remains
normal, and he completed a university degree in business
and management with second-class honors. Nerve con-
duction studies were performed in both siblings and
showed no evidence of demyelination of peripheral nerves
(Figure 1B).
Examination of the third affected individual in this fam-
ily (individual III-3) was very similar and consistent with a
spastic-ataxia phenotype. His first symptoms started at the
age of six months, when he presented with nystagmus and
hypotonia in the limbs. Symptoms progressed and
included delayed motor milestones, truncal and limb
ataxia, and dysarthria. At 8 years old he was already a
wheelchair user. A moderate pyramidal syndrome replaced
the hypotonia as the disease progressed (Supplemental
Movie S2).970 The American Journal of Human Genetics 100, 969–977, June 1,The second family is of Kenyan and Tanzanian origin
and has two affected siblings. Individual 4 (III-2) is
currently 44 years old and the oldest in our cohort. She pre-
sented with symptoms of nystagmus, gait ataxia, and
spasticity in the lower limbs at one year old. The MRI at
that time confirmed cerebellar and brainstem atrophy.
Currently, more than 40 years into her disease, she is
wheelchair bound and presents with cervical and lower-
limb dystonia, gross head titubation, hypometric saccades,
horizontal nystagmus in all directions of gaze, and limited
eye movements both horizontally and vertically. There is
truncal and limb ataxia with severe stiffness in the lower
limbs and very brisk reflexes (Supplemental Movie S3).
Sensation is normal. Her affected cousin had an almost
identical phenotype with a progressive spastic ataxia but
died young from tuberculosis.
Children (individuals 6 [IV-6] and 7 [IV-7]) of a third
consanguineous Saudi Arabian family presented with
nystagmus and developmental delay, most pronounced
in the motor domain. Physical examination was notable
for nystagmus and hypotonia that later progressed to spas-
ticity in the peripheries (Table 1).
MRI appearance was consistent between all seven cases
(Figure 1C). Themost striking finding was of hypomyelina-
tion with diffusely increased T2W and FLAIR signal in the
white matter and corresponding iso- to hyper-intense
signal on T1 images. Increased T2W signal was seen in
the periventricular white matter, globi pallidi, external
capsules, superior and inferior cerebellar peduncles, den-
tate hilus, and the pons. There was relative sparing of the
cortico-spinal tracts in the brainstem. Cerebellar atrophy
was found in adult cases, in addition to diffuse spinal
cord volume loss with abnormal T2W hyperintensity of
the ventral and dorsal horn cells of the spinal cord.
The individuals included in this study were recruited
along with the parents and unaffected siblings under
institutional-research-board-approved research protocols
(KFSHRC RAC#2060008 and UCLH 04/N034) with
informed consent. DNA was extracted from peripheral
blood. Extensive genetic, metabolic, and mitochondrial
investigations that excluded acquired and other inherited
causes were carried out for all families. Whole-exome
sequencing was conducted in the three families indepen-
dently and included samples from parents and from
affected and unaffected children. Variants were filtered
for homozygous, highly deleterious, rare mutations. After
mutations were prioritized according to the above criteria,
only one variant was segregating with the disease. It
revealed a homozygous premature stop mutation in
NKX6-2: c.121A>T; p.Lys41* (NM_177400.2) in families 1
and 2. There were no other variants that segregated with
the disease in these two families. Although these families
are not known to be related, we found that the same ho-
mozygous truncating variant in NKX6-2 fully segregated
with the disease in each family. In order to investigate
whether the p.Lys41* mutation was inherited on the
same haplotype, we performed homozygosity mapping2017
Table 1. Description of All Phenotypes Associated with NKX6-2 Mutations
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7
cDNA sequence c.121A>T c.121A>T c.121A>T c.121A>T c.121A>T c.487C>G c.487C>G
Amino-acid change p.Lys41* p.Lys41* p.Lys41* p.Lys41* p.Lys41* p.Leu163Val p.Leu163Val
Gender (male or female) F M M F M F M
Age at examination (in
years)
27 23 8 44 30 6 4
Age of onset (in years) 0.3 5 0.6 1 3 0.1 0.1
Disease duration 27 18 7 43 27 6 4
Disability score 4 3 3 4 4 4 4
Symptom at onset nystagmus ataxia nystagmus nystagmus nystagmus nystagmus nystagmus
Pyramidal syndrome yes yes yes yes yes yes yes
Cerebellar syndrome yes yes yes yes yes yes yes
Ashworth score (1–4) 3 3 2 3 2 3 3
Dystonia cervical, limbs cervical, limbs limbs cervical, limbs absent absent absent
Sensation normal normal normal normal normal normal normal
Eye movement Limitation of the eye
movements
Hypometric sacades,
nystagmus
Hypometric sacades,
nystagmus
Limitation of the eye
movements
hypometric sacades,
nystagmus
hypometric sacades,
nystagmus
hypometric sacades,
nystagmus
Cognitive function normal normal normal normal normal abnormal, severe global
psychomotor delay
abnormal, severe global
psychomotor delay
Brain MRI results cerebellar atrophy,
hypomyelination
cerebellar atrophy,
hypomyelination
cerebellar atrophy,
hypomyelination
cerebellar atrophy,
hypomyelination, thin
corpus callosum
not available white-matter changes,
hypomyelination
white-matter changes,
hypomyelination
Disability score was defined as follows: 0, asymptomatic; 1, able to walk but finds it difficult to run; 2, uses one stick and/or orthosis; 3, uses two sticks or a walker; 4, unable to walk and uses a wheelchair.
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
1
0
0
,
9
6
9
–
9
7
7
,
Ju
n
e
1
,
2
0
1
7
9
7
1
Figure 1. Identification of Three Families affected by Progressive Spastic Ataxia and Hypomyelination
(A) Pedigree of the families with NXK6-2 mutations.
(B) Results of nerve-conduction studies showing normal myelination of peripheral nerves in family 1.
(C) Magnetic resonance imaging findings in individuals with NKX6-2 mutations. Images 1 and 2 show Coronal T1W and FLAIR
sequences demonstrating periventricular FLAIR hyperintensity and corresponding iso- to hyper-intense T1W signal relative to gray
matter, suggestive of hypomyelination. Some hyperintensity of the dentate hilus is noted. Images 3 and 4 show axial T2Wand coronal
FLAIR sequences demonstrating abnormal T2W hyper-intense signal in the periventricular white matter, globi palladi, and external
capsules. Images 5 and 6 show coronal FLAIR demonstrating T2W hyperintensity in the periventricular white matter and superior cere-
bellar peduncles. An axial T2W sequence demonstrating hyperintensity of the inferior cerebellar penduncles is shown. Images 7–9 show
sagittal T2Wand T1Was well as axial T2W sequences indicating diffuse spinal-cord volume loss and abnormal T2Whyperintensity sym-
metrically affecting the gray matter of the ventral and dorsal horn cells. Images 10–13 show axial T1W and T2W sequences demon-
strating diffuse T2W hyperintensity and T1W iso- to hypo-intensity of the pons along with relative sparing of the cortico-spinal tracts.
There is disproportionate volume loss of the cerebellum as well as the superior andmiddle cerebellar peduncles. Images 14–17 show axial
T2W. A subtle T2W hyperintense signal change affects the anterior limbs of the internal capsules, thalami, and left peritrigonal white
(legend continued on next page)
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Figure 2. NKX6-2 Mutations
(A) Homozygosity mapping in families 1 and 2 identified four homozygous regions that were shared by the three affected individuals
from families 1 and 2. The region on chromosome 10 includes NKX6-2 (arrow) shared between the two families.
(B) Sanger sequencing confirming c.121A>T in the two families.
(C) Conservation of p. Lys41* across species.
(D) Homozygosity mapping in family 3 identified two homozygous regions that were shared by the affected individuals. The region on
chromosome 10 includes NKX6-2 (arrow).
(E) Sanger sequencing confirming c.487C>G and segregation in the family.
(F) Conservation of the p.Leu163Val residue within the NKX6-2 homeodomain across species. The mutation is marked in red above the
corresponding amino acid.
(G) Immunoblot analysis showing a complete absence of NKX6-2 in an affected individual (individual III-1 in family 1 in the pedigree)
compared to a control individual.in individuals from families 1 and 2. In total, we identified
four regions of homozygosity that were shared by the
three affected individuals; these included a 1.4 M
region that contains NKX6-2 on chromosome 10 (chr10:
134013906–35440214) (Figure 2A). Further genotype anal-
ysis confirmed the presence of a shared haplotype block
surrounding NKX6-2 (Supplementary Table S1), support-
ing the founder effect of the mutation. The c.121A>T mu-
tation is located in exon 1 and creates a premature stopmatter. The image shows a pontine diffuse T2W hyperintense signal
and superior cerebellar peduncles. Images 18–21 show axial and co
diffusely increased T2 signal intensity in cerebral and cerebellar wh
myelination in the youngest individuals.
The Amecodon at amino acid 41. This stop codon is predicted to
result in nonsense-mediated messenger RNA (mRNA)
decay (NMD) and the loss of the homeobox functional
domain. This mutation was not previously associated
with a human phenotype and was absent in our in-house
datasets of 1,284 ethnically matched exome-sequenced in-
dividuals and in public databases.5,6
Independently, autozygosity mapping was performed in
family 3. Although several autozygous intervals weresparing the cortico-spinal tracts and volume loss of the cerebellum
ronal T2 weighted spin echo and axial FLAIR images indicating
ite matter bilaterally and symmetrically, demonstrating delayed
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Figure 3. NKX6-2 Expression in Normal Developing Brain and Adult Brain
(A) NKX6-2 expression in different brain areas in adult pathologically normal human brains.8 NKX6-2 is expressed in all ten brain re-
gions; the highest expression is detected in white matter. Abbreviations are as follows: WHMT, white matter; MEDU, medulla; SNIG,
substantia nigra; THAL, thalamus; HIPP, hippocampus; PUTM, putamen; TCTX, temporal cortex; OCTX, occipital cortex; FCTX, frontal
cortex; and CRB, cerebellum.
(B) NKX6-2 expression in developing brain.9 Abbreviations are as follows: NCX, neocortex; STR, striatum; HP, hippocampus; AMY,
amygdala; MD, midbrain; and CBC, cerebellum.found to be shared between the two affected siblings, only
two were exclusive to them in comparison to the rest
of the family (Chr2:180761383–181784642 and Chr10:
133033315–135434551) (Figure 2D and Figure S1). Exome
sequencing was carried out in the index individual, and
variants were filtered by the homozygosity coordinates
as well as frequency (MAF < 0.001 when 2,363 Saudi
exomes and ExAC were used5) and potential gene effects
(splicing or coding excluding non-splicing synonymous).
Only one homozygous variant remained after applica-
tion of these filters: NKX6-2 (NM_177400.2; c.487C>G;
p.Leu163Val), and it fully segregated with the disease in
the family under a fully penetrant autosomal-recessive
model (Figure 2E). This variant was only present once in
the heterozygous state in our database and is absent in
ExAC.5 The p.Leu163Val variant replaces an absolutely
conserved leucine residue in the consensus homeobox
domain of the protein (Figure 2F). This residue is part of
an evolutionarily constrained element (Figure S2) and is
predicted to be deleterious and probably damaging by
SIFT and PolyPhen, respectively. The general structure of
homeodomains is helix-loop-helix-turn-helix. On the
basis of sequence similarity and in-silico modeling, the
p.Leu163Val mutation is predicted to lie within the first
helix and to be protein destabilizing (DUET7 DDG score:
1.418Kcal/mol). On the basis of amino acid conservation
between homeodomains, the leucine residue is predicted
to be highly conserved.974 The American Journal of Human Genetics 100, 969–977, June 1,We established a fibroblast cell line for individual 2 to
examine the effect of the truncating variant on NKX6-2
protein. Immunoblot analysis on the extracted protein re-
vealed complete absence of the expected 29 kDa band as
well as the hypothetical band representing the truncated
variant, which implies that the variant is probably null
(Figure 2G). The remarkably similar phenotype among in-
dividuals who are homozygous for a truncating, probably
null allele and those homozygous for a missense variant
suggests that the latter is a functional null allele. Taken
together, our results support the notion thatNKX6-2muta-
tions underlie the phenotype observed in the Saudi and
Indian families.
In humans, NKX6-2 is known to be expressed in devel-
oping and adult human brain (Figures 3A and 3B).
Although GTEx10 reports the highest expression in spinal
cord and substantia nigra, BRAINEAC8 suggests that intra-
lobular white matter expresses the most NKX6-2 mRNA
and that medulla and substantia nigra follow (Figure 3A).
Because NKX6-2 is known to be a transcription factor, we
investigated these findings further in silico by using the al-
gorithm for the reconstruction of accurate cellular net-
works (ARACNe) based on an adaptive partitioning (AP)
strategy. In this way, we identified NKX6-2’s most probable
target genes in human white matter (the location of
maximal expression). The resulting regulon, which con-
sisted of 407 predicted target genes, was significantly en-
riched for genes associated with development of the2017
Figure 4. A bottom-up Plot Showing a
Different Connectivity of NKX6-2 Com-
pared to PLP1 and FA2H, Suggesting a
Regulatory Role of NKX6-2
Seed genes associated with hereditary spas-
tic paraplegia contain an inner yellow
circle, whereas context genes are repre-
sented by inner blue circles. The context
genes in the plot are enriched for genes
that the algorithm for the reconstruction
of accurate cellular networks (ARACNe)
based on an adaptive partitioning (AP)
strategy predicts are found in the regulon
of NKX6-2 (23 out of 35, FET p value
2.2 3 1016).central nervous system (GO: 0007417, p value 0.0049) and
cytoskeletal protein binding (GO: 0008092, p value 6.0 3
104). Interestingly, within this gene set are transcription
factors known to be required for the generation of
mature postmitotic oligodendrocytes, namely NKX2-2
(MIM: 604612) and SOX10 (MIM: 602229).11 Furthermore,
when we used weighed genes co-expression analysis
(WGCNA) to create modules of highly co-expressed genes
and assessed the NKX6-2 regulon for enrichment within
these modules, we identified a significant overlap of the
genes within the regulon (Fisher’s Exact test) in three co-
expression modules (black, brown and salmon) all en-
riched for oligodendrocytes markers (p value 0.03, 7.2 3
1012 and 1.13 3 10126, respectively). These findings
strongly suggest that in keeping with the mouse model,
NKX6-2 is a transcription factor involved in the matura-
tion of oligodendrocytes in humans.
We extended our analysis further to place NKX6-2 within
the context of known Mendelian disorders. Within the
NKX6-2 regulon, we identified 72 genes that are already
linked to a Mendelian disorder within the Online Mende-
lian Inheritance in Man (OMIM) database. Among this list
we identified FA2H and PLP1 (Spastic Paraplegia 35 (MIM:
612319) and Pelizaeus-Merzbacher Disease (MIM: 312080))
as well as five genes in which mutations are associated
with peripheral demyelinating disorders (PMP22 [MIM:
601097], LITAF [MIM: 601098], NDRG1 [MIM: 601455],
SH3TC2 [MIM: 601596], SOX10 [MIM: 609136], and YARS
[MIM: 608323]) (Figure 4). Given these findings, we used
the tool Phenomizer to identify a set of known Mendelian
disorders with significant phenotypic similarity to individ-The American Journal of Humanuals with bi-allelic NKX6-2 mutations
and check for enrichment of this
gene set among the 72 genes and asso-
ciated disorders identified within the
NKX6-2 regulon. Remarkably, we
found that the NKX6-2 regulon was
significantly enriched for disorders
with high phenotypic similarity to
our individuals (p value 0.00079).
Thus, as well as demonstrating that
bi-allelic mutations in NKX6-2 pro-duce a hypomyelinating disorder, these findings imply
that among the remaining 335 genes within the NKX6-2
regulon, there are likely to be other gene mutations associ-
ated with disorders involving myelin generation and main-
tenance in the central nervous system.
NKX6-2 is a member of the NKX protein family of tran-
scription factors, which have established roles during the
development of an organism. Awatramani et al. have
demonstrated the important role of NKX6-2 as a gene-
repressor transcription factor regulating oligodendrocyte
gene expression in mouse oligodendrocytes.12 Further-
more, they show that NKX6-2 is working in tandem with
several other genes involved in myelination,12 supporting
our findings that NKX6-2 acts within the same pathways
of genes already associated with myelination. The homeo-
box is a highly conserved 180 bp DNA-binding domain
that mediates specific contact with the minor and
major grooves of DNA in a strictly sequence-specific
fashion.13–15 It is likely that disrupting this sequence by re-
placing the highly conserved leucine residue will disrupt
DNA binding. All known functions of NKX6-2 are thought
to be mediated through its transcription activity in the nu-
cleus. We note that the equivalent residue in NKX6-1
(p.Leu521) (MIM: 602563) is also invariant in humans, as
evident from the 60,709 individuals whose sequence data
are available through ExAC.5 It is conceivable that the cere-
bellar atrophy represents a more severe phenotype only
seen in those with bi-allelic truncation. However, these
individuals are generally much older than the two young
siblings with the missense variant, so it might also repre-
sent an age-related phenotype.Genetics 100, 969–977, June 1, 2017 975
NKX6-2 was originally identified in the search for novel
homeobox-domain-containing genes when the mouse
embryonic cDNA library was probed.16 The strong expres-
sion in the postnatal glial cells and testes of mouse promp-
ted the original name GTX.16 Although there are three
members of NKX6 (1–3), NKX6-2 is mostly related to
NKX6-1, with which it shares significant structure homol-
ogy and overlapping domains of expression.12 The duo
NKX6-2 and NKX6-1 has been extensively studied in the
context of class II homeodomain transcription factors,
which are induced by SHH (MIM: 600725) in the course
of neural-tube patterning to confer ventral progenitor
cell identities.17,18 Both genes are co-expressed initially in
a broad ventral domain, but their expression later becomes
mutually exclusive, in part because of the repression of
NKX6-2 by NKX6-1.19 Although NKX6-2 deficiency causes
de-repression of DBX1 and a resulting increase in V0 and
decrease in V1 neurons, there was no net loss of motor
neurons, and the apparent lack of a discernible phenotype
in Nkx6-2/ mice was assumed to be caused by redun-
dancy withNKX6-1.19 The redundancy model is supported
by the observation that although there is significant devel-
opmental arrest of motor neurons in Nkx6-1/ mice, this
arrest is compounded in double mutants.19,20
Although the above studies were helpful in defining the
location of NKX6-2 in the developmental network during
neural tube development, they suggested that its role was
most likely dispensable. However, Southwood generated
another knockout mouse line that provided critical insight
into the indispensable role of NKX6-2.21 In addition to
confirming the previously established strong expression
ofNKX6-2 in the brain and spinal cord, they demonstrated
a strong and long-lasting expression in oligodendrocytes
well into adulthood.21 Importantly, loss of NKX6-2 was
found to result in significantmotor and behavioral deficits.
This phenotype was delayed postnatally and coincided
with the timing of maximum myelination, which promp-
ted the investigation of myelin in these mice. Significant
abnormalities, including hypomyelinated and even naked
axons, were noted in myelin, although they were less
marked than those caused by other gene knockouts, e.g.,
md rats, quaking mice, and Mag-null and Cgt-null
mice.22–24 Not only were these abnormalities seen in all
examined white-matter tracts, but they also were extended
to the cranial nerves, including the optic nerve.
The phenotype we observe in individuals with bi-allelic
deleterious variants in NKX6-2 is supported by the previ-
ously published data on mouse and oligodendrocyte
NKX6-2 deficiency12,21,25 in several aspects. Most conspic-
uous is the resemblance in myelin pathology, which we
also note to be relatively mild in comparison to classical
hypomyelinating leukodystrophies. Of particular rele-
vance is the specific reference by Southwood et al. that
the optic nerve myelin is significantly decreased given
the prominent and universal nystagmus phenotype in
our individuals. Nystagmus is a common feature of hypo-
myelinating and demyelinating disorders, and although976 The American Journal of Human Genetics 100, 969–977, June 1,the pathogenesis is not fully understood, it is thought to
be caused by impaired visual feedback loops during devel-
opment.26 Also relevant is the finding that motor neurons
in the spinal cord develop with only subtle perturbation
from their progenitors in Nkx6-2/ mice; this perturba-
tion appears to be recapitulated in affected individuals
who have no evidence of lower motor-neuron disease.
Furthermore, on the basis of in silico analysis, gene-reg-
ulatory networks, and co-expression data in humans, we
show that NKX6-2 is involved in the genesis and develop-
ment of oligodendrocytes. These findings are mirrored in
the clinical phenotype of NKX6-2-mutated individuals
who clinically progress and then remain static after myeli-
nation is complete. Most importantly, in agreement with
previous work on animal and cell models,25 we provide
evidence that within the NKX6-2 regulon there are other
genes already linked to Mendelian disorders associated
with spastic-ataxia and/or hypo or de-myelination. Apart
from placing the NKX6-2 within the myelin regulation
pathway as previously reported and linking it to a human
Mendelian disorder when that pathway is disrupted, our
data suggest that other such genes in the NKX6-2 regulon
could be involved in central myelination and cause dis-
eases in humans.
In conclusion, we show that the NKX6-2 is recurrently
mutated in several families and individuals with a spas-
tic-ataxia and hypomyelinating leukodystrophy pheno-
type. After development and in adolescence, the pheno-
type stabilizes clinically. This syndrome confirms the
non-redundant role of NKX6-2 in myelin homeostasis in
the central nervous system and expands the genetic causes
of spastic ataxia, the heterogeneity of developmental
genes, and inborn errors of myelin metabolism in humans.Supplemental Data
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